financetom
SEPA
financetom
/
Financials
/
SEPA
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
SEP Acquisition Corp.SEPA
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

SEP Acquisition Corp. does not have significant operations.

The company intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses.

The company was formerly known as Mercury Ecommerce Acquisition Corp. and changed its name to SEP Acquisition Corp. in December 2022.

SEP Acquisition Corp. was incorporated in 2021 and is based in Houston, Texas. SEP Acquisition Corp. operates as a subsidiary of Mercury Sponsor Group I LLC.

Latest News >
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
Dec 20, 2024
Dec 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' ( LXRX ) add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday. ...
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Dec 20, 2024
Dec 20 - Japanese drugmaker Nippon Shinyaku ( NPNKF ) infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday. The jury also rejected competing patent claims by Shinyaku, which had accused Sarepta of violating its patent rights in its DMD drug Viltepso....
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
Dec 20, 2024
Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's ( LLY ) weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder. The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. Sleep...
Arch Capital Renews $1 Billion Share Repurchase Program
Arch Capital Renews $1 Billion Share Repurchase Program
Dec 20, 2024
04:40 PM EST, 12/20/2024 (MT Newswires) -- Arch Capital Group ( ACGL ) said Friday it has renewed its share repurchase authorization of $1.0 billion, which may be effected from time to time in open market or privately negotiated transactions. The company said the new program replaces its existing buyback authorization. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved